The portfolio of contracts signed Selvita in 2016. Is currently 36.0 million zł – the company said. Selvita expects an increase in revenues from service by approx. 30 percent.
A year ago, the portfolio of orders for 2015. Amounted to 31.8 million zł.
Selvita generated in 2015 . 55.7 million zł revenue and 6.2 million zł net profit. After adjustment due to the impact of one-off events (plan expenses and the change in deferred income tax) amounted to 7.7 million zł.
“We want to make in 2016. Revenue service in our segment increased by approximately . 30 per cent. ” – Said at the conference, the company’s CEO Paul Przewięźlikowski.
Sales Services segment in 2015. Amounted to 25.6 million zł, 59 percent. more yoy. Innovative segment generated 15.4 million zł (an increase of 21 percent. Yoy) and grant funding increased by 18 percent. yoy to 14.7 million zł.
Selvita also assumes in 2016. begin clinical trials molecule SEL24 and conduct preclinical studies on SEL120.
the President reiterated that the company wants to sign at least one big contract partneringowy this year.
the company is also working on opening a laboratory in Poznan.
laboratory in Poznan is scheduled to start operations in late August and September and the first to have an area of approx. 500 sq.m. . (at the end of 2015. company had laboratories with an area of 2.7 thousand. sq. m). By the end of 2017. Selvita wants to double the surface in Poznan and employ 50-100 people there.
“We want this year to open at least one foreign branch sales in Europe. The cost of the unit is approx. 1 million zł per year “- said the president.
Currently Selvita has branches sales in Boston, San Francisco and Cambridge in the UK.
” Boston each other earns, the United Kingdom is near, while the San Francisco yet burden our results, “- he said. (PAP)
mj / ana /
No comments:
Post a Comment